Pricing Log in Create free account
Friday 6 November 2026 Export AVTR’s income statement to Excel — free account

Avantor, Inc.

AVTR Healthcare Medical Instruments & Supplies

Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024.

Revenue
+4.59%
EPS
+128.9%
Free cash flow
−9.03%
Total debt
−4.51%

Quarter to September 2026, against a year earlier

15.14 0.51 −3.26%
Market cap
$10.3B
P/E
30.3×
Fwd P/E
34.8×
Dividend yield
—
F-score
4/9
Altman Z
1.55
Beneish M
−2.91
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Avantor, Inc. 10-Q filed Oct 28, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 9:03 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 29, 2026: 7 added · 4 removed · 38 modified; 16 with only figures updated

  1. Modified · Overview

    During the three months ended JuneSeptember 30, 2026, we recorded net sales of $1,692.31,698.3 million, net income of $38.1203.4 million, Adjusted EBITDA of $254.3256.9 million, operating income of $121.8139.5 million, and Adjusted Operating Income of $225.1227.6 million. Net sales for the three months ended JuneSeptember 30, 2026 increased by 0.54.6%, which included a 0.45.2% organic net sales decreaseincrease compared to the same period in 2025. See “Reconciliations of non-GAAP measures” for reconciliations of net income (loss) to Adjusted EBITDA, net income (loss) margin to Adjusted EBITDA margin, operating income to Adjusted Operating Income, and operating income margin to Adjusted Operating Income margin. See “Results of operations” for a reconciliation and explanation of changes of net sales growth (decline) to organic net sales growth (decline).